AMENDED AND RESTATED EXCLUSIVE PREFERRED PARTNER, CO-PROMOTION, DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • August 10th, 2023 • DarioHealth Corp. • Surgical & medical instruments & apparatus • New York
THIS AMENDED AND RESTATED COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of July 10, 2023 (the “Restatement Date”), by and between Sanofi US Services, Inc., a Delaware corporation, with a place of business located at Head Office 55 Corporate Drive, Bridgewater, NJ 08807, United States (“Sanofi”) and Dario Health Corp., a Delaware corporation with a place of business located at 18 West 18th Street, New York 10011, United States (“Dario”). Sanofi and Dario are each referred to individually as a “Party” and collectively as the “Parties”.
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT By and Between DBV TECHNOLOGIES and NESTEC S.A.Development Collaboration and License Agreement • March 22nd, 2017 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
This DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (together with the exhibits hereto, this “Agreement”) is entered into on this 27th day of May, 2016 (the “Effective Date”), by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”). NESTEC and DBV may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NUMBER ONE TO DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • May 3rd, 2016 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus
This Amendment Number One to Development Collaboration and License Agreement (this “Amendment”) is entered into effective as of January 18, 2016 (the “Amendment Effective Date”) by and among Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc., a Delaware corporation having a principal place of business at 5964 La Place Court, Carlsbad, CA 92008 (“GenMark”), Advanced Liquid Logic, Inc., a Delaware corporation having its principal place of business at 5200 Illumina Way, San Diego, CA 92122 (“ALL”), and Illumina, Inc., a Delaware corporation having a principal place of business at 5200 Illumina Way, San Diego, CA 92122 (“Illumina”). GenMark, ALL and Illumina are hereinafter and in the Agreement (as defined below) referred to individually as a “Party” and collectively as the “Parties” (subject to the qualification below relating to Illumina). Capitalized terms used but not defined herein shall have the meaning given to such terms in the Agreement.
Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [***]) has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.Development Collaboration and License Agreement • February 28th, 2022 • Compugen LTD • Biological products, (no disgnostic substances) • New York
This Research and Development Collaboration and License Agreement (the “Agreement”), effective as of 5 August, 2013 (the “Effective Date”), is entered into by and between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at Muellerstrasse 178, 13353 Berlin, Germany (“Bayer”) and Compugen Ltd a company formed under the laws of Israel, having a place of business at 72 Pinchas Rosen Street, Tel Aviv 69512, Israel (“Compugen”). Bayer and Compugen each shall be referred to herein as a “Party” and they shall be referred to together as the “Parties.”
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • March 22nd, 2013 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California
The Corporation renounces any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of any holder of Series D Preferred that is a strategic operating company, or any director, stockholder, employee or agent of such entity.
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • November 8th, 2012 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California
This Development Collaboration and License Agreement (“Agreement”) is made and entered into as of the 26th day of July, 2012 (the “Effective Date”) by and between Advanced Liquid Logic, Inc., a Delaware corporation having its principal office at 615 Davis Drive, Suite 800, Morrisville NC, 27560 (“ALL”), and Clinical Micro Sensors, Inc., d/b/a Genmark Diagnostics, Inc., a Delaware corporation having its principal office at 5964 La Place Court, Carlsbad, CA 92008 (“GenMark”). ALL and GenMark may each be referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT BETWEENDevelopment Collaboration and License Agreement • December 10th, 1997 • Alteon Inc /De • Pharmaceutical preparations • California
